Global Inflammatory Bowel Disease Market - 2023-2030

Market Overview

The Global Inflammatory Bowel Disease Market reached US$ 19 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 26.7 billion by 2030. The Global Inflammatory Bowel Disease Market is expected to exhibit a CAGR of 4.4% during the forecast period 2023-2030.

Inflammatory Bowel Disease (IBD) is a group of chronic disorders that cause inflammation in the digestive tract. The two main types of IBD are Crohn's disease and ulcerative colitis. Several classes of drugs are used to treat Inflammatory Bowel Disease (IBD), including anti-inflammatory medications, immunomodulating drugs, and biologics.

Furthermore, the advent of biologics and targeted therapies have revolutionized the treatment landscape for IBD, increased awareness about IBD among patients, increased healthcare expenditure in developed and developing economies and increased FDA approvals are the factors expected to drive the market over the forecast period.

Market Dynamics

The Increasing FDA Approvals of IBD Drugs are Boosting the Global Inflammatory Bowel Disease Market Growth During the Forecast Period

In April 2023, AbbVie announced the European Commission (EC) approved RINVOQ (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) as the first oral Janus Kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Similarly, in March 2023, Sandoz, a leading global company in generic pharmaceuticals and biosimilars, received approval from the US Food and Drug Administration (FDA) for a citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz (adalimumab-adaz) injection.

This citrate-free HCF of adalimumab is approved to treat seven conditions covered by the reference medicine Humira (adalimumab). These conditions include rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Thus, from the above factors, the market is expected to drive over the forecast period.

The Expiration Of Patents for Certain Branded IBD Drugs is Hampering the Growth of the Global Inflammatory Bowel Disease Market in the Forecast Period

The expiration of patents for certain branded IBD drugs can lead to increased competition from generic versions, resulting in price erosion and reduced market share. For instance, with the expiration of the key patent on Humira by the end of 2022, regulators have approved a competitor's version of the drug, signaling the entry of more generic alternatives into the market. This increased competition is expected to drive down the price of the medication.

Furthermore, a fifth copy of AbbVie's blockbuster biologic drug Humira has been approved in Europe, intensifying competition among manufacturers of more affordable biotech drugs. Mylan and Fujifilm Kyowa Kirin Biologics have received the green light from the European Commission to market their version of the injectable medicine, named Hulio, and they plan to launch it in Europe after October 16, which marks the expiration of AbbVie's primary European patent on Humira.

Hence, owing to the above factors, the market is expected to hamper over the forecast period.

COVID-19 Impact Analysis

The inflammatory bowel disease market has experienced significant disruptions due to the COVID-19 pandemic. Concerns about immunosuppression and increased susceptibility to COVID-19 have influenced treatment decisions for IBD patients.

Physicians and patients have had to weigh the risks and benefits of immunosuppressive therapies. In some cases, treatment plans, such as reducing corticosteroid use or adjusting immunosuppressive dosages, were modified to minimize the potential impact on the immune system.

The pandemic has caused delays or disruptions in IBD clinical trials. Recruitment of participants, site visits, and data collection were affected due to restrictions on in-person interactions and prioritization of resources for COVID-19-related research. This has led to delays in the development and availability of new IBD therapies.

In contrast, the pandemic has accelerated the adoption of telemedicine as an alternative to in-person visits. Many IBD patients have turned to telemedicine for consultations and follow-ups with healthcare providers. While this has provided a means for continued care, it may have limitations regarding physical examinations and invasive procedures typically part of routine IBD care. These combined factors have had a notable impact on the inflammatory bowel disease market dynamics.

Russia-Ukraine Conflict Analysis

The ongoing conflict between Russia and Ukraine has significantly impacted the IBD market. Geopolitical conflicts can potentially disrupt global supply chains, including the production and distribution of pharmaceutical products. If supply chain disruptions occurred during the Russia-Ukraine war, it could have led to shortages or delays in the availability of IBD medications.

In times of conflict or geopolitical tensions, healthcare priorities often shift. Governments and healthcare systems may allocate resources and funding to address immediate crisis needs, potentially diverting attention and resources from conditions like IBD. Consequently, research, development, and investments in IBD treatments and therapies may be affected.

Furthermore, geopolitical conflicts can lead to trade disruptions and the imposition of sanctions by different countries. Trade restrictions or sanctions can impact the import and export of pharmaceutical products, potentially affecting the availability and cost of IBD medications in various markets.

Segment Analysis

The global inflammatory bowel disease market is segmented based on type, route of administration, drug class, distribution channel, and region.

The Aminosalicylates Segment is Expected To Hold a Dominant Position in the Market Over the Forecast Period

The aminosalicylates segment accounted for the highest market share, accounting for approximately 23.2% of the inflammatory bowel disease market in 2022. Aminosalicylates are commonly used to induce and maintain remission in mild to moderate cases of IBD, particularly in ulcerative colitis. They work by reducing inflammation in the gastrointestinal tract.

Aminosalicylates are generally well-tolerated and have a favorable safety profile. They are often used as the initial treatment for IBD, and their effectiveness varies depending on the individual and the specific disease characteristics.

Two examples of aminosalicylates used in the treatment of IBD are mesalamine (5-ASA) and sulfasalazine. Mesalamine is available in various oral and rectal formulations and is commonly prescribed for mild to moderate cases of ulcerative colitis. Sulfasalazine, a combination of sulfapyridine and 5-ASA, is primarily used to treat mild to moderate ulcerative colitis cases. Both medications work by reducing inflammation in the gastrointestinal tract.

Research conducted by Crohn's & Colitis UK in 2022 suggests 1 in every 123 people in the UK have either Crohn's disease or ulcerative colitis. This amounts to a total of nearly half a million people in the UK living with IBD. Therefore, although IBD is not that common, it still impacts many people in the UK.

Therefore, there is an increase in demand for aminosalicylates drug class. Thus , the market segment is expected to hold the largest market share over the forecast period due to the above factors.

Geographical Analysis

The Growing Clinical Trials, Increasing FDA Approvals, and Better Reimbursement Policies Dominate the North American Region

North America is expected to dominate the inflammatory bowel disease market, accounting for around 40.4% of this market. For instance, Alimentiv Inc. is conducting a phase-IV open-label, randomized study involving participants with Crohn's disease (CD) in remission. The study aims to compare the effectiveness of continuing 5-ASA therapy versus withdrawing 5-ASA in maintaining CD remission over 24 months. The estimated completion date for the study is June 2026.

Furthermore, on May 9, 2023, Eli Lilly and Company has released new investigational data on mirikizumab, a potential treatment for moderately to severely active ulcerative colitis (UC). These data, presented at Digestive Disease Week (DDW) in Chicago, provide further evidence of the efficacy and safety of mirikizumab based on previous pivotal studies.

The data presented at DDW included an interim analysis of mirikizumab as induction therapy in pediatric patients with moderately to severely active UC from the Phase 2 SHINE-1 study. Additionally, a new analysis was conducted on the LUCENT-1 and LUCENT-2 studies, focusing on the association between bowel urgency remission and the impact on the quality of life in adults with UC as assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ) scores.

Hence , the North American region is expected to hold the largest market share over the forecast period due to the above factors.

Competitive Landscape

The major global players in the market include: AbbVie Inc, Takeda Pharmaceutical Company Limited, Pfizer Inc, Biogen, Novartis AG, Eli Lilly Company, Merck & Co., Inc., Johnson & Johnson, Biocon Ltd., and Sanofi.

Why Purchase the Report?

• To visualize the global inflammatory bowel disease market segmentation based on the type, route of administration, drug class, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous inflammatory bowel disease market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Inflammatory Bowel Disease Market Report Would Provide Approximately 69 Tables, 68 Figures And 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies